Michael Ulz

Q: What is Michael Ulz's success rate?

Michael Ulz currently has a success rate of 83.92475398634063.

Q: What is the average return of Michael Ulz's calls?

Their stock ratings have generated an average return of 20.13154739610669.

Baird | Healthcare

Michael Ulz is an analyst from Baird specializing in the Healthcare sector. Ranked #1127 out of 4601 analysts, they have issued 23 stock ratings with a success rate of 83.92% and an average return of 20.13%.

Michael Ulz has a well-established track record, with 23 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 83.92% and an average return of 20.13%, underscoring their expertise and ability to identify winning opportunities for investors.

#1127

Out of 4601

Total Ratings

+83.92%

Success Rate

+20.13%

Average Return

Recent Ratings Analysis

KPTI

Buy

Mar 25, 2026

Target

$15.00

Current

$5.89

Performance

13.05%

Michael Ulz rated KPTI as Outperform on Mar 25, 2026, setting a price target of 15. The call has proven timely, with shares rising 13.05% toward the price target of 15.

CABA

Buy

Mar 24, 2026

Target

$13.00

Current

$2.96

Performance

10.86%

On Mar 24, 2026, CABA was given a Overweight rating by Michael Ulz, with a target price of 13. The stock rallied 10.86% after the rating, narrowing the gap to the target of 13 and validating the bullish stance.

DYN

Buy

Mar 03, 2026

Target

$50.00

Current

$18.84

Performance

29.04%

DYN received a Overweight rating from Michael Ulz on Mar 03, 2026, aiming for 50. Momentum has favored the Buy call, with shares climbing from 18.84 to 18.84, rewarding those who trusted the recommendation.

AARD

Hold

Mar 02, 2026

Target

$29.00

Current

$4.30

Performance

-21.39%

On Mar 02, 2026, Michael Ulz published a Equal-Weight outlook on AARD, with a target of 29. Weakness in the stock, now at 4.3, supported the conservative rating.

ALNY

Hold

Jan 30, 2026

Target

$408.00

Current

$318.85

Performance

-5.68%

Michael Ulz on Jan 30, 2026 assigned ALNY a Equal-Weight rating, with a price target of 408. The call successfully avoided chasing as shares lost 5.68%.

MIRM

Buy

Jan 30, 2026

Target

$123.00

Current

$94.17

Performance

-8.77%

On Jan 30, 2026, Michael Ulz reaffirmed MIRM with a Overweight rating, targeting 123. Shares slid 8.77% despite the recommendation, highlighting downside risks.

GUTS

Hold

Jan 30, 2026

Target

$2.00

Current

$0.46

Performance

-0.89%

GUTS was rated Equal-Weight by Michael Ulz on Jan 30, 2026, with a price objective of 2. Flat performance suggests the Hold view was reasonable.

ARWR

Hold

Jan 07, 2026

Target

$81.00

Current

$61.03

Performance

-7.09%

On Jan 07, 2026, Michael Ulz initiated coverage on ARWR with a Equal-Weight rating and target of 81. The rating matched the stock’s inability to hold above 61.03.

KYTX

Buy

Dec 04, 2025

Target

$25.00

Current

$8.87

Performance

13.14%

Michael Ulz issued a Overweight recommendation for KYTX on Dec 04, 2025, price target set at 25. Investors following the Buy call captured upside momentum, with shares now at 8.87.

IONS

Buy

Oct 30, 2025

Target

$94.00

Current

$74.79

Performance

0.84%

On Oct 30, 2025, IONS was evaluated by Michael Ulz, who gave a Overweight rating and target of 94. So far, the Buy call awaits clearer momentum, with shares flat at 74.79.

VKTX

Buy

Oct 23, 2025

Target

$102.00

Current

$34.80

Performance

2.59%

Michael Ulz rated VKTX as Overweight on Oct 23, 2025, setting a price target of 102. Shares have remained stable near 34.8, leaving the 102 target still in play.

SLN

Buy

Mar 05, 2025

Target

$45.00

Current

$5.94

Performance

25.58%

On Mar 05, 2025, SLN was given a Overweight rating by Michael Ulz, with a target price of 45. The stock rallied 25.58% after the rating, narrowing the gap to the target of 45 and validating the bullish stance.

YMAB

Sell

Mar 05, 2025

Target

$7.00

Current

$8.61

Performance

77.53%

YMAB received a Underweight rating from Michael Ulz on Mar 05, 2025, aiming for 7. Shares declined 77.53%, matching the cautious outlook.

IOVA

Buy

Feb 28, 2025

Target

$20.00

Current

$3.43

Performance

-19.10%

On Feb 28, 2025, Michael Ulz published a Outperform outlook on IOVA, with a target of 20. Market action contradicted the Buy thesis, as shares slipped to 3.43.

THRD

Hold

Feb 12, 2025

Target

$5.00

Current

$5.38

Performance

51.55%

Michael Ulz on Feb 12, 2025 assigned THRD a Equal-Weight rating, with a price target of 5. Shares outperformed expectations, climbing 51.55% despite the neutral view.

AKRO

Buy

Jan 28, 2025

Target

$96.00

Current

$54.65

Performance

6.18%

On Jan 28, 2025, Michael Ulz reaffirmed AKRO with a Overweight rating, targeting 96. The recommendation was supported by strong follow-through as the stock rose from 54.65 to 54.65.

BPMC

Hold

Jul 12, 2024

Target

$115.00

Current

$129.46

Performance

9.92%

BPMC was rated Equal-Weight by Michael Ulz on Jul 12, 2024, with a price objective of 115. Despite caution, upside momentum rewarded risk-takers with gains to 129.46.

Frequency Asked Questions

Who is Michael Ulz?

Michael Ulz is an analyst from Baird specializing in the Healthcare sector.

What is Michael Ulz's success rate?

Michael Ulz currently has a success rate of +83.92%.

How many ratings has Michael Ulz issued?

Michael Ulz has issued 23 stock ratings so far.

What is the average return of Michael Ulz's calls?

Their stock ratings have generated an average return of +20.13%.

What is Michael Ulz's ranking?

Michael Ulz is ranked #1127 out of 4601 analysts.

What types of ratings does Michael Ulz give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Michael Ulz?

You can follow Michael Ulz by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Michael Ulz?

Their latest rating was a Buy on KPTI issued on 2026-03-25.